Display options
Share it on

Genes Cancer. 2016 Nov;7(11):414-425. doi: 10.18632/genesandcancer.125.

The regulation of tumor suppressor protein, p53, and estrogen receptor (ERα) by resveratrol in breast cancer cells.

Genes & cancer

Julieta Saluzzo, Kelly M Hallman, Katie Aleck, Brigitte Dwyer, Meghan Quigley, Viktoria Mladenovik, Amy E Siebert, Sumi Dinda

Affiliations

  1. School of Health Sciences, Oakland University, Rochester, MI, USA; Prevention Research Center, Oakland University, Rochester, MI, USA.

PMID: 28191286 PMCID: PMC5302041 DOI: 10.18632/genesandcancer.125

Abstract

Resveratrol (RES) is a natural antioxidant found abundantly in grapes, peanuts, and berries, and is known to possess anti-tumorigenic properties. However, there is a noticeable lack of studies on the mechanistic effects of Resveratrol on tumor suppressors. Previous studies from our laboratory have shown the tumor suppressor protein p53 and estrogen receptor-alpha (ERα) to be possible molecular targets for RES. In this study, the anti-estrogenic effects of RES were analyzed on the expression of ERα and p53. The breast cancer cells grown in stripped serum were treated with 60 μM RES, as the optimum concentration based on data obtained from a concentration study using 1-100 μM RES. Our studies indicate that RES caused a decrease in the levels of protein expression of p53 and ERα as compared to the control. Increasing concentrations of RES caused a four-fold decrease in cell number in comparison to estradiol. RES, in conjunction with ICI 182,780 (ICI), caused a down-regulation of both p53 and ERα as compared to the control. These observed effects on cell proliferation and regulation of both p53 and ERα by RES may lead to further understanding of the relationship between tumor suppressor proteins and steroid receptors in breast cancer cells.

Keywords: Breast cancer; antiestrogens; estrogen; p53; tumor suppressors

Conflict of interest statement

None

References

  1. Syst Biol Reprod Med. 2011 Dec;57(6):279-87 - PubMed
  2. Climacteric. 2014 Dec;17(6):682-91 - PubMed
  3. Endocr Res. 2009;34(4):101-8 - PubMed
  4. EMBO J. 2001 Mar 15;20(6):1331-40 - PubMed
  5. Mol Oncol. 2013 Oct;7(5):859-69 - PubMed
  6. Pharmacology. 2007;80(2-3):134-43 - PubMed
  7. Oncol Rep. 2004 Feb;11(2):441-6 - PubMed
  8. Cancer Res. 2012 Sep 1;72(17):4574-86 - PubMed
  9. Int J Cancer. 2011 Dec 1;129(11):2732-43 - PubMed
  10. Int J Cancer. 2003 May 1;104(5):587-96 - PubMed
  11. PLoS One. 2012;7(11):e48746 - PubMed
  12. J Agric Food Chem. 2012 Jun 13;60(23):5693-708 - PubMed
  13. Cancer. 2008 May 15;112(10):2130-42 - PubMed
  14. Science. 1997 Jan 10;275(5297):218-20 - PubMed
  15. Oncogene. 2002 Jan 24;21(5):761-8 - PubMed
  16. Life Sci. 1997;61(21):2103-10 - PubMed
  17. Genes Dev. 1998 Sep 15;12(18):2831-41 - PubMed
  18. Int J Oncol. 2006 Mar;28(3):641-8 - PubMed
  19. Climacteric. 2015;18(4):574-81 - PubMed
  20. FASEB J. 2006 Aug;20(10):1742-4 - PubMed
  21. Climacteric. 2014 Aug;17(4):385-92 - PubMed
  22. Clin Chim Acta. 1995 Mar 31;235(2):207-19 - PubMed
  23. J Steroid Biochem Mol Biol. 2004 Mar;88(3):223-34 - PubMed
  24. J Biol Chem. 1995 Dec 1;270(48):28507-10 - PubMed
  25. J Nutr Biochem. 2010 Sep;21(9):856-64 - PubMed
  26. Biochem Biophys Res Commun. 1994 Aug 15;202(3):1413-9 - PubMed

Publication Types